N/A
N=34
Food Preference Following Bariatric Surgery
Obesity
Bottom Line
View on ClinicalTrials.gov: NCT03363581 ↗Enrolled (actual)
34
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcome: Primary: Total Food Intake (Lunch Buffet) at 24 Months — 2540.1; 721 kJ
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Food Preference (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Imperial College London
- Primary completion
- Sep 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Food Intake (Lunch Buffet) at 24 Months |
2540.1; 721 | — |
| PRIMARY Change in Absolute Intake of Fat |
-1549.7; 301 | — |
| PRIMARY Change in Absolute Intake of Carbohydrates |
-2088.6; 280 | — |
| PRIMARY Change in Absolute Intake of Sugar |
-890.7; 160.0 | — |
| PRIMARY Change in Absolute Intake of Protein |
-360.7; 140.2 | — |
Summary
Roux-en-Y gastric bypass (RYGB) decreases appetite, caloric intake, glycemia, and body weight, all of which are maintained long term.It is controversial whether, after RYGB, patients choose to eat less high fat and sugary foods in favor of lower energy dense alternatives. Therefore the proposition to use direct measures in humans after RYGB to test the hypothesis that the selection and intake of foods varying in fat content and glycemic index, as well as the pattern of ingestion within and across meals, changes in a manner that leads to beneficial outcomes on body weight.
Eligibility Criteria
Inclusion Criteria
- Surgical and non-surgical groups:
A) Bariatric surgery B) Controls with no history of bariatric surgery
- Independently mobile
- Capacity to consent to participate
- >18 years of age
Exclusion Criteria
- Pre-operatively: significant dysphagia, gastric outlet obstruction or anything that prevents subjects from eating a meal.
- Post-operatively: significant and persistent surgical complications or anything that prevents subjects from eating a meal.
- Systemic or gastrointestinal condition which may affect food intake or preference, including:
i) pregnancy or ii) breast feeding.
- Active and significant psychiatric illness including substance misuse
- Significant cognitive or communication issues
- Medications with documented effect on food intake or food preference
- History of significant food allergy and certain dietary restrictions
- History of liver disease or pancreatitis
- History of bradyarrythmia or congestive cardiac failure group)
- Use of medications with potential serious interactions with Octreotide
Data sourced from ClinicalTrials.gov (NCT03363581). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.